London · Delayed Price · Currency is GBP · Price in GBX Synthomer Earnings Call Transcripts
Fiscal Year 2025
-
Margins and cash flow improved in 2025 despite lower revenue, with cost savings and specialty focus driving resilience. Divestments and refinancing strengthened the balance sheet, while Q1 2026 showed strong trading momentum and upside risks for the year.
-
Gross margin and EBITDA improved despite an 8.8% revenue decline, driven by cost reductions and portfolio simplification. Demand remains subdued due to tariffs and geopolitical uncertainty, but positive free cash flow is expected in H2, with leverage reduction a key focus.
Fiscal Year 2024
-
Revenue, EBITDA, and EBIT all grew in 2024 despite weak end-market demand, with all divisions posting volume gains and specialty products now 55% of revenues. Positive free cash flow and further deleveraging are expected in 2025, supported by cost actions, portfolio shifts, and disciplined capital allocation.
-
H1 2024 saw revenue, earnings, and EPS growth, driven by volume recovery and self-help measures, with stable trading and improved margins across all divisions. Strategic transformation and divestments continue, while leverage and liquidity remain within targets.